Literature DB >> 19693433

Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains.

Janet van Eersel1, Mian Bi, Yazi D Ke, John R Hodges, John H Xuereb, Gillian C Gregory, Glenda M Halliday, Jürgen Götz, Jillian J Kril, Lars M Ittner.   

Abstract

Frontotemporal lobar degeneration (FTLD) is a common cause of presenile dementia characterised by behavioural and language disturbances. Pick's disease (PiD) is a subtype of FTLD, which presents with intraneuronal inclusions consisting of hyperphosphorylated tau protein aggregates. Although Alzheimer's disease (AD) is also characterised by tau lesions, these are both histologically and biochemically distinct from the tau aggregates found in PiD. What determines the distinct characteristics of these tau lesions is unknown. As phosphorylated, soluble tau has been suggested to be the precursor of tau aggregates, we compared both the level and phosphorylation profile of tau in tissue extracts of AD and PiD brains to determine whether the differences in the tau lesions are reflected by differences in soluble tau. Levels of soluble tau were decreased in AD but not PiD. In addition, soluble tau was phosphorylated to a greater extent in AD than in PiD and displayed a different phosphorylation profile in the two disorders. Consistently, tau kinases were activated to different degrees in AD compared with PiD. Such differences in solubility and phosphorylation may contribute, at least in part, to the formation of distinct tau deposits, but may also have implications for the clinical differences between AD and PiD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693433     DOI: 10.1007/s00702-009-0293-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

1.  Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments.

Authors:  M E King; N Ghoshal; J S Wall; L I Binder; H Ksiezak-Reding
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study.

Authors:  Victoria Zhukareva; Sonali Sundarraj; David Mann; Magnus Sjogren; Kaj Blenow; Christopher M Clark; Daniel W McKeel; Alison Goate; Carol F Lippa; Jean-Paul Vonsattel; John H Growdon; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2003-01-25       Impact factor: 17.088

3.  Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules.

Authors:  A C Alonso; I Grundke-Iqbal; K Iqbal
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

4.  Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells.

Authors:  Valérie Buée-Scherrer; Michel Goedert
Journal:  FEBS Lett       Date:  2002-03-27       Impact factor: 4.124

5.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

6.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

Review 7.  Animal models of Alzheimer's disease and frontotemporal dementia.

Authors:  Jürgen Götz; Lars M Ittner
Journal:  Nat Rev Neurosci       Date:  2008-07       Impact factor: 34.870

Review 8.  Pick body disease and Pick syndrome.

Authors:  Toshiki Uchihara; Kenji Ikeda; Kuniaki Tsuchiya
Journal:  Neuropathology       Date:  2003-12       Impact factor: 1.906

9.  Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.

Authors:  Y P Wang; J Biernat; M Pickhardt; E Mandelkow; E-M Mandelkow
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  18 in total

1.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

2.  Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Authors:  P Lei; S Ayton; A T Appukuttan; S Moon; J A Duce; I Volitakis; R Cherny; S J Wood; M Greenough; G Berger; C Pantelis; P McGorry; A Yung; D I Finkelstein; A I Bush
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

3.  Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease.

Authors:  Jesper Riise; Niels Plath; Bente Pakkenberg; Anna Parachikova
Journal:  J Neural Transm (Vienna)       Date:  2015-02-14       Impact factor: 3.575

Review 4.  Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-07-22       Impact factor: 17.088

Review 5.  Biometals and their therapeutic implications in Alzheimer's disease.

Authors:  Scott Ayton; Peng Lei; Ashley I Bush
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

Review 6.  Is tau ready for admission to the prion club?

Authors:  Garth F Hall; Brian A Patuto
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

7.  Lessons from tau-deficient mice.

Authors:  Yazi D Ke; Alexandra K Suchowerska; Julia van der Hoven; Dineeka M De Silva; Christopher W Wu; Janet van Eersel; Arne Ittner; Lars M Ittner
Journal:  Int J Alzheimers Dis       Date:  2012-06-06

8.  Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons.

Authors:  Janet van Eersel; Yazi D Ke; Amadeus Gladbach; Mian Bi; Jürgen Götz; Jillian J Kril; Lars M Ittner
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

Review 9.  Interaction between α-synuclein and other proteins in neurodegenerative disorders.

Authors:  Kurt A Jellinger
Journal:  ScientificWorldJournal       Date:  2011-10-24

10.  Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Yazi D Ke; Fabien Delerue; Amadeus Gladbach; Jürgen Götz; Lars M Ittner
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.